TIAA CREF Investment Management LLC Has $746,000 Stake in Minerva Neurosciences, Inc (NERV)

TIAA CREF Investment Management LLC lifted its position in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) by 69.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,245 shares of the biopharmaceutical company’s stock after purchasing an additional 34,572 shares during the period. TIAA CREF Investment Management LLC owned 0.23% of Minerva Neurosciences worth $746,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of NERV. Bank of New York Mellon Corp boosted its holdings in shares of Minerva Neurosciences by 1.6% during the first quarter. Bank of New York Mellon Corp now owns 80,201 shares of the biopharmaceutical company’s stock worth $649,000 after purchasing an additional 1,286 shares during the period. Vanguard Group Inc. lifted its holdings in Minerva Neurosciences by 13.4% in the first quarter. Vanguard Group Inc. now owns 939,297 shares of the biopharmaceutical company’s stock worth $7,608,000 after buying an additional 110,876 shares during the period. Geode Capital Management LLC lifted its holdings in Minerva Neurosciences by 7.9% in the first quarter. Geode Capital Management LLC now owns 137,443 shares of the biopharmaceutical company’s stock worth $1,113,000 after buying an additional 10,010 shares during the period. Renaissance Technologies LLC lifted its holdings in Minerva Neurosciences by 325.0% in the first quarter. Renaissance Technologies LLC now owns 69,700 shares of the biopharmaceutical company’s stock worth $565,000 after buying an additional 53,300 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in Minerva Neurosciences by 54.6% in the second quarter. Russell Investments Group Ltd. now owns 15,794 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 5,579 shares during the period. Institutional investors own 76.72% of the company’s stock.

Shares of Minerva Neurosciences, Inc (NASDAQ NERV) opened at $5.15 on Wednesday. Minerva Neurosciences, Inc has a 1-year low of $4.80 and a 1-year high of $14.15.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter. During the same period last year, the firm posted ($0.24) EPS. analysts anticipate that Minerva Neurosciences, Inc will post -1.28 earnings per share for the current fiscal year.

NERV has been the subject of several research analyst reports. Zacks Investment Research lowered shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Friday, August 25th. Citigroup Inc. initiated coverage on shares of Minerva Neurosciences in a report on Friday, September 1st. They issued a “buy” rating and a $11.00 price objective for the company. Finally, BidaskClub lowered shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $13.94.

ILLEGAL ACTIVITY NOTICE: “TIAA CREF Investment Management LLC Has $746,000 Stake in Minerva Neurosciences, Inc (NERV)” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://transcriptdaily.com/2017/11/15/tiaa-cref-investment-management-llc-has-746000-stake-in-minerva-neurosciences-inc-nerv.html.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply